Again, I cannot resolve the debate within that field (except to keep calling for data collection) but I disagree a bit with Alex. The people with deep/appropriate expertise calling for delaying the booster aren't that few. That said, very thoughtful/leading people also disagree.
One, at least Moderna is absolutely within the capability of many, many LMIC. (Pfizer/BioNTech, not so much). Two, if rich countries stretch Moderna/Pfizer more, that's a lot more of the rest for LMIC. Doesn't resolve question but equity side has that to consider.
-
-
I'm all for increasing supply to solve the problem, but we're in front of the queue, and having the debate with that luxury and as someone from the global south, I cannot understate how jarring I find it that this is not a bigger priority here since it's so obvious.
-
My perspective is looking at what, e.g., Gates is funding. Their focus is firmly on global, and not local, health. And what Gates is (appears to be) focused on are safe and effective vaccine candidates that can be produced, distributed, and administered at scale.
End of conversation
New conversation -
-
-
I don't buy that for a moment. Moderna is already well behind their production targets.
-
If rich countries can do with less, supply (of other vaccines) for poorer countries will be more. I didn't say there was an excess now because there's clearly a shortage now *everywhere*, and hence the painful discussions of trade-offs, but it's pretty straightforward.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.